Anti-dementia medications: Fighting a losing battle?
| Autor: | Micov Ana, Pecikoza Uroš |
|---|---|
| Jazyk: | srbština |
| Rok vydání: | 2020 |
| Předmět: | |
| Zdroj: | Arhiv za farmaciju, Vol 70, Iss 2, Pp 55-68 (2020) |
| Druh dokumentu: | article |
| ISSN: | 0004-1963 2217-8767 37067028 |
| DOI: | 10.5937/arhfarm2002055M |
| Popis: | Alzheimer's disease (AD), the most common cause of dementia, is growing health, social and economic issue because of the increasing number of sufferers, limited efficacy of available treatment options, and high total healthcare costs. It is clinically characterized by cognitive and behavioral impairments, both of which need to be treated appropriately to improve patients' quality of life and their caregivers as well. Currently, available anti-dementia medications provide only modest and transient cognitive benefits. Donepezil, rivastigmine and galantamine (cholinesterase inhibitors) are indicated for the symptomatic management of mild to moderately severe AD, while memantine (NMDA glutamate receptors antagonist) is recommended for moderate-to-severe AD. A special focus on behavioral symptoms (e.g. anxiety, depression, aggression) management is required as they cause great suffering in patients/caregivers. The use of medications that can impair cognitive function, such as drugs with anticholinergic activity, should be avoided in patients with dementia. Additionally, interventions that could delay or prevent dementia onset in some subjects are focused on minimizing modifiable risk factors (hypertension, diabetes, depression) and maximizing protective factors (physical activity, healthy diet, leisure, and social activities). The treatment of AD remains a challenge. |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|